Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
clinical deteriorationclinical improvementdeathsPCR-negative conversion
favipiravir 6- 0.60 [0.16; 2.26], 2 RCTs, I2=17%
inconclusive result
1.12 [0.02; 62.74], 1 RCT, I2=0%
inconclusive result
0.98 [0.21; 4.57], 2 RCTs, I2=32%
inconclusive result
Renin-angiotensin-system-acting agents6 OBS 0.73 [0.24; 2.24], 2 studies, I2=63%
inconclusive result
- OBS 0.59 [0.38; 0.92], 4 studies, I2=0%
very low degree of certainty
-
chloroquine and derivatives3-- 0.66 [0.01; 35.52], 1 RCT, I2=0%
inconclusive result
OBS 16.33 [2.80; 95.27], 1 study, I2=0%
low degree of certainty
baloxavir marboxil1----
hydroxychloroquine plus macrolides1-- OBS 1.14 [0.56; 2.32], 1 study, I2=0%
inconclusive result
-
remdesivir1- 1.32 [1.12; 1.55], 1 RCT, I2=0%
moderate degree of certainty
0.70 [0.47; 1.04], 1 RCT, I2=0%
inconclusive result
-
umifenovir (arbidol)1----
ASC09/ritonavir0----
azithromycin0----
azvudine0----
carrimycin0----
danoprevir / ritonavir0----
darunavir cobicistat0----
darunavir/cobicistat plus chloroquine0----
doxycycline0----
fluvoxamine0----
ivermectin0----
leronlimab0----
lopinavir / ritonavir plus ribavirin0----
lopinavir/ritonavir0----
lopinavir/ritonavir plus chloroquine0----
lopinavir/ritonavir plus interferon ß-1a0----
lopinavir/ritonavir, ribavirin and interferon beta-1b0----
meplazumab0----
nitazoxanide0----
oseltamivir0----
oseltamivir plus chloroquin0----
ribavirin0----
ritonavir0----
sofosbuvir and daclatasvir0----
tenofovir/emtricitabine0----
tenofovir/emtricitabine plus hydroxychloroquine0----
tranexamic acid0----
triazavirin0----